OverviewSuggest Edit

Myrexis (formerly known as Myriad Pharmaceuticals) is a molecular biopharmaceutical company. It discovers, develops, and commercializes therapies for the treatment of cancer. The company is also engaged in identifying, evaluating, and making financial investments in life sciences assets.


Latest Updates

Share Price (Mar 2020)$0 (+3%)

Myrexis Financials and Metrics

Myrexis Revenue

Market capitalization (27-Mar-2020)


Closing stock price (27-Mar-2020)

Myrexis's current market capitalization is $324.3 k.
Show all financial metrics

Myrexis Online and Social Media Presence

Embed Graph

Myrexis Frequently Asked Questions

  • When was Myrexis founded?

    Myrexis was founded in 1999.

  • Who are Myrexis competitors?

    Competitors of Myrexis include Mirati Therapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.